MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Omeros Corp

Închisă

SectorSănătate

3.36 -2.89

Rezumat

Modificarea prețului

24h

Curent

Minim

3.33

Maxim

3.46

Indicatori cheie

By Trading Economics

Venit

-2.1M

-33M

Vânzări

412K

412K

Marjă de profit

-8,121.359

Angajați

202

EBITDA

-1.9M

-35M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+158.62% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-192M

230M

Deschiderea anterioară

6.25

Închiderea anterioară

3.36

Sentimentul știrilor

By Acuity

68%

32%

334 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Omeros Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 iul. 2025, 21:01 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 20:46 UTC

Câștiguri

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 iul. 2025, 20:39 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 20:36 UTC

Câștiguri

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 iul. 2025, 20:16 UTC

Achiziții, Fuziuni, Preluări

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 iul. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 iul. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 iul. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 iul. 2025, 18:24 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 iul. 2025, 18:19 UTC

Câștiguri

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 iul. 2025, 18:11 UTC

Achiziții, Fuziuni, Preluări

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 iul. 2025, 18:11 UTC

Câștiguri

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 iul. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 iul. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 iul. 2025, 16:28 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 iul. 2025, 16:22 UTC

Câștiguri

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Energy & Utilities Roundup: Market Talk

18 iul. 2025, 16:20 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

18 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 iul. 2025, 16:04 UTC

Câștiguri

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 iul. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 iul. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 iul. 2025, 15:47 UTC

Market Talk
Câștiguri

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparație

Modificare preț

Omeros Corp Așteptări

Obiectiv de preț

By TipRanks

158.62% sus

Prognoză pe 12 luni

Medie 9 USD  158.62%

Maxim 9 USD

Minim 9 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmeros Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

1

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

6.265 / 7.49Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

334 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.